Related Experiment Video
Updated: Aug 28, 2026

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
Published on: March 24, 2017
Systems pharmacology reveals type I interferon and myeloid-like B cell reprogramming as candidate druggable axes in
Bin Sun1, Yiqiao Lu2, Wei Liu3
1Wuxi No. 2 People's Hospital, Jiangnan University Medical Center, Wuxi, China.
Abstract:
Antiphospholipid syndrome (APS) lacks disease-modifying targeted therapies, and its molecular heterogeneity remains poorly characterized. We employed an integrative systems pharmacology approach combining weighted gene co-expression network analysis (WGCNA), single-cell RNA sequencing, Connectivity Map (CMap) screening, and molecular docking to prioritize candidate therapeutic targets in APS. WGCNA of purified-neutrophil bulk RNA-seq (n = 18), with module preservation confirmed in whole blood (n = 88), identified two disease-associated modules: ME10 (176 genes, r = 0.77, interferon-I signaling) and ME2 (3409 genes, r = 0.79, degranulation/innate activation). Single-cell analysis of 26,936 B cells revealed transitional B cells with elevated ME2 scores and aberrant SPI1 expression, suggesting myeloid-like transcriptional reprogramming. CMap analysis ranked chloroquine - a 4-aminoquinoline antimalarial closely related to hydroxychloroquine, which is recommended as adjunctive therapy in APS - among top ME2 candidates (NCS = -2.07), supporting the biological relevance of the screen. DrugBank mapping identified 14 FDA-approved drugs targeting module genes, and a 3-gene machine learning signature (CORO1A, ANKRD22, IFITM1) achieved cross-tissue validation AUC of 0.802. External datasets supported ME2 pathway modulation by NAPc2 intervention and cross-tissue module conservation in platelets. Patient-level ME10 x ME2 stratification revealed four molecular subtypes with distinct pathway activation profiles. This framework prioritizes candidate targets across both IFN-I and degranulation pathways, generating hypotheses for pathway-guided therapeutic development that require experimental and clinical validation.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenomics: Identification of New Drug Targets
Phosphoinositides and PIPs
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
EPS and iPS Cells in Disease Research